Anti-VEGF Agents — MCQs
During angiogenesis, what factors are responsible for the recruitment of pericytes and periendothelial cells?
In which of the following conditions does IOL implantation after cataract surgery require the greatest caution and specialized management?
In diabetic retinopathy, which layer of the retina is primarily affected?
Which of the following drugs is approved for treatment of both relapsing-remitting AND primary progressive multiple sclerosis?
Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
What is the mechanism of action of Bevacizumab?
A 56 year old patient presents after 3 days of cataract surgery with a history of increasing pain and diminution of vision after an initial improvement. The most likely cause would be:
Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?
Treatment of choice for clinically significant macular edema in a diabetic is?
Anti-VEGF Agents Indian Medical PG Practice Questions and MCQs
Question 1: During angiogenesis, what factors are responsible for the recruitment of pericytes and periendothelial cells?
- A. VEGF & PDGF
- B. Angiopoietins, TGF & PDGF (Correct Answer)
- C. VEGF, IL-2, IL-6
- D. TGF, VEGF & PDGF
Explanation: ***Angiopoietins, TGF & PDGF*** - **Angiopoietins** are crucial for the stabilization of blood vessels and recruitment of **pericytes**, enhancing vessel maturation [1]. - **TGF (Transforming Growth Factor)** and **PDGF (Platelet-Derived Growth Factor)** also play significant roles in the recruitment and proliferation of **pericytes** and periendothelial cells during angiogenesis [1]. *VEGF & PDGF* - While **VEGF (Vascular Endothelial Growth Factor)** is important for endothelial cell migration and proliferation, it does not directly recruit **pericytes** alone. - This combination lacks **angiopoietins**, which are key for the stabilization of newly formed blood vessels [1]. *VEGF, IL-2, IL-6* - **IL-2** and **IL-6** are primarily associated with immune responses and do not directly contribute to pericyte recruitment during angiogenesis. - **VEGF** alone supports endothelial cells but does not effectively recruit **pericytes** without the cooperation of other factors. *TGF, VEGF & PDGF* - Although both **TGF** and **PDGF** are involved in pericyte recruitment [1], the absence of **angiopoietins** limits the effectiveness of this combination for the recruitment process. - **VEGF** alone does not facilitate direct recruitment of **pericytes**, as it mainly focuses on endothelial cells. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 115-116.
Question 2: In which of the following conditions does IOL implantation after cataract surgery require the greatest caution and specialized management?
- A. Fuchs' heterochromic iridocyclitis
- B. Psoriatic arthritis
- C. Reiter's syndrome
- D. Juvenile rheumatoid arthritis (Correct Answer)
Explanation: ***Juvenile rheumatoid arthritis*** - Patients with **juvenile rheumatoid arthritis (JRA)**, particularly those with **pauciarticular JRA** and **ANA positivity**, are at high risk for developing chronic uveitis, which can lead to significant cataract formation and severe postoperative complications. - Due to the high risk of severe postoperative inflammation, glaucoma, and vision loss, IOL implantation in JRA patients requires extensive preoperative optimization of inflammation and careful intraoperative/postoperative management. *Fuchs' heterochromic iridocyclitis* - This condition presents with chronic, low-grade, **non-granulomatous anterior uveitis** and often leads to cataract formation. - While IOL implantation in these patients is generally well-tolerated, it does not pose the same high risk of severe postoperative inflammation and complications as seen in JRA-associated uveitis. *Psoriatic arthritis* - Psoriatic arthritis can be associated with acute anterior uveitis, but it typically presents as an acute, intermittent inflammation. - The risk of chronic, severe uveitis leading to complex cataract surgery and significant postoperative complications is not as consistently high or as severe as in JRA. *Reiter's syndrome* - Reiter's syndrome (now part of **reactive arthritis**) is another seronegative spondyloarthropathy that can cause acute anterior uveitis. - Similar to psoriatic arthritis, the uveitis is usually acute and self-limiting, and while ocular inflammation needs to be controlled, the risk profile for IOL implantation is not as challenging as in JRA.
Question 3: In diabetic retinopathy, which layer of the retina is primarily affected?
- A. Layer of rods and cones
- B. Retinal pigment epithelium
- C. Outer plexiform layer
- D. Inner nuclear layer (Correct Answer)
Explanation: ***Inner nuclear layer*** - The inner nuclear layer contains the **retinal capillary network**, which is the primary site of pathology in diabetic retinopathy. - **Microangiopathy** (pericyte loss, basement membrane thickening, endothelial cell damage) occurs in the capillaries located within this layer. - **Microaneurysms**, the earliest ophthalmoscopic sign of diabetic retinopathy, form from damaged capillaries in the inner nuclear layer. - **Diabetic macular edema (DME)** involves fluid accumulation that begins at the level of the capillaries in the inner nuclear and inner plexiform layers, then extends to the outer plexiform layer. *Outer plexiform layer* - This layer is **secondarily affected** by leakage from damaged capillaries in deeper retinal layers (inner nuclear and inner plexiform layers). - **Hard exudates** (lipid and protein deposits) accumulate in the outer plexiform layer as a consequence of capillary leakage, but this is not the primary site of vascular pathology. - The outer plexiform layer itself has minimal vasculature and is not where the initial microvascular changes occur. *Layer of rods and cones* - Photoreceptors are affected only in advanced stages of diabetic retinopathy due to chronic ischemia and secondary damage. - The primary pathology is vascular and occurs in the inner retinal layers where capillaries are located, not in the avascular photoreceptor layer. *Retinal pigment epithelium* - The RPE is not directly affected by the microvascular changes that characterize diabetic retinopathy. - RPE dysfunction is more characteristic of **age-related macular degeneration (AMD)** and other degenerative conditions. - In diabetic retinopathy, the RPE may be affected indirectly in very advanced cases but is not a primary site of pathology.
Question 4: Which of the following drugs is approved for treatment of both relapsing-remitting AND primary progressive multiple sclerosis?
- A. Fingolimod
- B. Omalizumab
- C. Ocrelizumab (Correct Answer)
- D. Natalizumab
Explanation: ***Ocrelizumab*** - This **anti-CD20 monoclonal antibody** is uniquely approved for both **relapsing-remitting MS (RRMS)** and **primary progressive MS (PPMS)**. - It targets **CD20-expressing B cells**, providing comprehensive disease modification across different MS phenotypes. *Fingolimod* - This **sphingosine 1-phosphate receptor modulator** is approved only for **relapsing-remitting MS**, not primary progressive MS. - While effective for RRMS, it lacks the **dual indication** that makes Ocrelizumab the most comprehensive treatment option. *Omalizumab* - This **anti-IgE monoclonal antibody** is used for **severe allergic asthma** and **chronic idiopathic urticaria**. - It has **no role in multiple sclerosis treatment** and works through IgE-mediated allergic pathways unrelated to MS pathophysiology. *Natalizumab* - This **integrin receptor antagonist** is used for MS but is typically reserved as **second-line therapy** due to **PML risk**. - Unlike Ocrelizumab, it is **not approved for primary progressive MS** and requires careful monitoring for serious complications.
Question 5: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
- A. Cyclophosphamide
- B. Methotrexate
- C. Cisplatin (Correct Answer)
- D. Dacarbazine
Explanation: ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**. - It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel. *Methotrexate* - **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis. - While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death. - It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines. *Dacarbazine* - **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma. - It is **not indicated for the treatment of ovarian carcinoma**.
Question 6: What is the mechanism of action of Bevacizumab?
- A. Anti VEGF antibody (Correct Answer)
- B. Histone deacetylase inhibitor
- C. HER2 neu inhibitor
- D. Proteasome inhibitor
Explanation: ***Anti VEGF antibody*** - **Bevacizumab** is a **monoclonal antibody** that specifically targets and binds to vascular endothelial growth factor (VEGF). - By inhibiting VEGF, bevacizumab prevents the formation of new blood vessels (**angiogenesis**) that tumors need to grow and metastasize. *Histone deacetylase inhibitor* - **Histone deacetylase (HDAC) inhibitors** influence gene expression by modifying chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - They are used in certain hematologic malignancies and solid tumors but do not directly interfere with angiogenesis. *Proteasome inhibitor* - **Proteasome inhibitors** like bortezomib block the action of proteasomes, leading to an accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. - This mechanism is distinct from blocking new blood vessel formation. *HER2 neu inhibitor* - **HER2 neu inhibitors** (e.g., trastuzumab) specifically target the HER2/neu receptor, which is overexpressed in certain breast and gastric cancers. - Their action primarily involves blocking growth signals transmitted through this receptor, not inhibiting VEGF or angiogenesis.
Question 7: A 56 year old patient presents after 3 days of cataract surgery with a history of increasing pain and diminution of vision after an initial improvement. The most likely cause would be:
- A. Endophthalmitis (Correct Answer)
- B. Central retinal vein occlusion
- C. Posterior capsular opacification (PCO)
- D. Retinal detachment
Explanation: ***Endophthalmitis*** - **Endophthalmitis** is a severe inflammation of the intraocular fluids (vitreous and aqueous humor), most commonly caused by infection following cataract surgery. - The presentation of **increasing pain** and **diminution of vision** a few days after initial improvement is a classic sign of acute post-operative endophthalmitis. *Central retinal vein occlusion* - **Central retinal vein occlusion (CRVO)** typically causes sudden, painless vision loss. - It is not commonly associated with **increasing pain** or a temporal relationship to recent cataract surgery in this manner. *Posterior capsular opacification (PCO)* - **Posterior capsular opacification (PCO)** develops weeks or months after cataract surgery, not within a few days. - It presents as gradual, painless blurring of vision without significant pain. *Retinal detachment* - **Retinal detachment** typically presents with sudden vision loss, flashes of light (photopsia), and floaters. - While it can occur after cataract surgery, it is less likely to present with **increasing pain** as the primary symptom described.
Question 8: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Explanation: ***Linagliptin*** - Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion. - This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment. - It is the **only DPP-IV inhibitor** that does not require dose modification in CKD. *Sitagliptin* - **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**. - Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients. *Vildagliptin* - **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**. - Not recommended in severe renal impairment (eGFR <50 mL/min). *Saxagliptin* - **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**. - Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
Question 9: In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?
- A. Prevention of recurrences of myocardial infarction
- B. Prevention of venous thrombosis and pulmonary embolism (Correct Answer)
- C. Prevention of cerebrovascular accident (stroke)
- D. Retinal artery thrombosis
Explanation: ***Prevention of venous thrombosis and pulmonary embolism*** - Anticoagulants are highly effective in inhibiting the formation and extension of **venous thrombi**, thereby directly preventing **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**. - The mechanism of action targets the **coagulation cascade**, directly reducing the risk of these venous thromboembolic events, which are a major indication for anticoagulant therapy. *Prevention of recurrences of myocardial infarction* - While anticoagulants may play a secondary role, **antiplatelet agents** (e.g., aspirin, clopidogrel) are the primary therapy for preventing recurrent myocardial infarction, as **arterial thrombi** are predominantly platelet-rich. - Anticoagulants are used in specific high-risk situations post-MI (e.g., **atrial fibrillation**, left ventricular thrombus) but are not generally considered the primary preventive strategy. *Cerebrovascular accident* - The benefit of anticoagulants for stroke prevention is primarily significant in cases of **cardioembolic stroke** (e.g., due to **atrial fibrillation**) where they prevent clot formation in the heart. - For non-cardioembolic **ischemic strokes** (e.g., thrombotic or lacunar), antiplatelet agents are generally preferred for secondary prevention. *Retinal artery thrombosis* - **Retinal artery thrombosis** is often caused by **arterial atherosclerosis** and **embolism** from the carotid arteries or heart, where antiplatelet agents are typically primary. - The role of anticoagulants here is limited to specific causes like **atrial fibrillation** or in patients already on anticoagulation for other indications.
Question 10: Treatment of choice for clinically significant macular edema in a diabetic is?
- A. Intravitreal anti-VEGF injections (Correct Answer)
- B. Control of Diabetes
- C. Panretinal Photocoagulation
- D. Focal Photocoagulation
Explanation: ***Intravitreal anti-VEGF injections*** - **Anti-VEGF agents** (e.g., ranibizumab, aflibercept) are the first-line treatment for **clinically significant diabetic macular edema (DME)** as they effectively reduce vascular leakage and improve vision. - They target **vascular endothelial growth factor (VEGF)**, a key mediator of increased vascular permeability and neovascularization in diabetic retinopathy. *Control of Diabetes* - While essential for preventing the **progression of diabetic retinopathy** and overall health, it is not the primary direct treatment for *existing* clinically significant macular edema. - Good glycemic control can reduce the *risk* of developing DME but does not acutely resolve established edema. *Panretinal Photocoagulation* - **Panretinal photocoagulation (PRP)** is primarily used for **proliferative diabetic retinopathy (PDR)** to ablate ischemic retina and reduce neovascularization. - It is not the treatment of choice for macular edema, as it can sometimes worsen macular function and visual acuity due to treatment-induced damage. *Focal Photocoagulation* - **Focal laser photocoagulation** was historically used for DME, targeting discrete leaking microaneurysms. - While effective for specific focal leakage, it has largely been superseded by **anti-VEGF injections** due to their superior efficacy in diffuse edema and better visual outcomes, especially when edema involves the fovea.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free